

Elie El Rassy

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6178969/elie-el-rassy-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141
papers

1,200
citations

18
h-index

26
g-index

170
ext. papers

1,784
ext. citations

3.7
avg, IF

5.4
L-index

#	Paper	IF	Citations
141	Systematic review of fetal and placental metastases among pregnant patients with cancer.. <i>Cancer Treatment Reviews</i> , 2022 , 104, 102356	14.4	0
140	Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. <i>Proteomes</i> , 2022 , 10, 16	4.6	4
139	Systematic review of the CUP trials characteristics and perspectives for next-generation studies.. <i>Cancer Treatment Reviews</i> , 2022 , 107, 102407	14.4	2
138	Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies. <i>Cancers</i> , 2022 , 14, 2449	6.6	0
137	The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. <i>Cancer Epidemiology</i> , 2021 , 75, 102045	2.8	3
136	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. <i>Annals of Translational Medicine</i> , 2021 , 9, 423	3.2	1
135	Comparative genomic characterization of melanoma of known and unknown primary. <i>Clinical and Translational Oncology</i> , 2021 , 23, 2302-2308	3.6	3
134	Targeting the VEGF Pathway in Osteosarcoma. <i>Cells</i> , 2021 , 10,	7.9	3
133	Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13583	4.6	2
132	The Contribution of the European School Of Oncology Education to the Central Asian and Caucasian Regions. <i>Journal of Cancer Education</i> , 2021 , 1	1.8	0
131	Unraveling the Wide Spectrum of Melanoma Biomarkers. <i>Diagnostics</i> , 2021 , 11,	3.8	20
130	The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey. <i>Future Oncology</i> , 2021 , 17, 151-157	3.6	1
129	The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2021 , 26, 389-396	5.7	3
128	Melanoma of unknown primary: New perspectives for an old story. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 158, 103208	7	9
127	Learning by Debate: Innovative Tool in the Hematology-Oncology Fellowship Program. <i>Journal of Cancer Education</i> , 2021 , 1	1.8	
126	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events. <i>JAMA Oncology</i> , 2021 , 7, 1573-1574	13.4	0
125	Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	10

124	Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2021 , 125, 1486-1493	8.7	4
123	Chemotherapy in the management of periosteal osteosarcoma: A narrative review. <i>Journal of Bone Oncology</i> , 2021 , 30, 100389	4.5	0
122	The Impact of Social Media on Daily Medical Practice in the Middle East and North Africa. <i>Annals of Thoracic Surgery</i> , 2021 , 112, 1384	2.7	1
121	Impact and Cost-Effectiveness of Oncotype DX for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer. <i>gulf journal of oncology, The</i> , 2021 , 1, 27-35	0.4	
120	The management of patients with metastatic prostate cancer during the COVID-19 pandemic. <i>Future Oncology</i> , 2020 , 16, 1455-1461	3.6	4
119	Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review. <i>Oncology Research and Treatment</i> , 2020 , 43, 299-306	2.8	7
118	A comprehensive overview of promising biomarkers in stage II colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102059	14.4	4
117	What can we learn from cancer of unknown primary in canine oncology?. <i>Journal of Advanced Research</i> , 2020 , 24, 495-500	13	2
116	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. <i>Drugs in R and D</i> , 2020 , 20, 55-73	3.4	40
115	Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920907504	5.4	48
114	Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 153, 103029	7	11
113	A comprehensive review on the diagnosis and management of intimal sarcoma of the pulmonary artery. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 147, 102889	7	11
112	Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?. <i>British Journal of Cancer</i> , 2020 , 122, 1124-1132	8.7	24
111	New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 147, 102882	7	12
110	The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. <i>European Journal of Cancer</i> , 2020 , 127, 118-122	7.5	14
109	Progress in refining the clinical management of cancer of unknown primary in the molecular era. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 541-554	19.4	30
108	TRK inhibition in soft tissue sarcomas: A comprehensive review. <i>Seminars in Oncology</i> , 2020 , 47, 73-84	5.5	4
107	Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?. <i>Annals of Translational Medicine</i> , 2020 , 8, 1710	3.2	9

106	Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. <i>Annals of Translational Medicine</i> , 2020 , 8, 1709	3.2	4
105	Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?. <i>Annals of Translational Medicine</i> , 2020 , 8, 1706	3.2	8
104	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 64, 162-174	1.4	17
103	Wise Management of Ovarian Cancer: On the Cutting Edge. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	32
102	Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice. <i>Bulletin Du Cancer</i> , 2020 , 107, 410-416	2.4	
101	Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes. <i>Current Oncology Reports</i> , 2020 , 22, 124	6.3	3
100	Should we screen patients with hematologic malignancies for COVID-19?. <i>Hematological Oncology</i> , 2020 , 38, 648-653	1.3	
99	Screening Strategies for COVID-19 in Patients With Hematologic Malignancies. <i>Frontiers in Oncology</i> , 2020 , 10, 1267	5.3	4
98	The diagnostic challenges of patients with carcinoma of unknown primary. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 775-783	3.5	4
97	Overview on the role of preoperative therapy in the management of kidney cancer. <i>Clinical and Translational Oncology</i> , 2020 , 22, 11-20	3.6	2
96	Cancer of unknown primary: Incidence rates, risk factors and survival among adolescents and young adults. <i>International Journal of Cancer</i> , 2020 , 146, 1490-1498	7.5	10
95	Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. <i>Investigational New Drugs</i> , 2020 , 38, 181-193	4.3	44
94	Diagnostic Value of TLE1 in Synovial Sarcoma: A Systematic Review and Meta-Analysis. <i>Sarcoma</i> , 2020 , 2020, 7192347	3.1	10
93	ALK gene rearrangement status in non-squamous non-small cell lung carcinoma in the Middle Eastern population. <i>gulf journal of oncology, The</i> , 2020 , 1, 38-44	0.4	1
92	Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2019 , 15, 909-923	3.6	8
91	Familial cancer of unknown primary. <i>International Journal of Clinical Oncology</i> , 2019 , 24, 1328-1331	4.2	9
90	A new entity of abdominal squamous cell carcinoma of unknown primary. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13111	4.6	8
89	A Novel Surgical Intervention for an Uncommon Entity: Laparoscopy-Assisted Resection of a Vaginal Septum in Obstructed Hemivagina and Ipsilateral Renal Anomaly Syndrome. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2019 , 29, 714-716	2.1	1

88	Lung cancer and immunotherapy: a real-life experience from second line and beyond. <i>Future Oncology</i> , 2019 , 15, 3025-3032	3.6	6
87	Advances in the management of brain metastases from cancer of unknown primary. <i>Future Oncology</i> , 2019 , 15, 2759-2768	3.6	3
86	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. <i>Immunotherapy</i> , 2019 , 11, 1149-1160	3.8	8
85	The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?. <i>Immunotherapy</i> , 2019 , 11, 913-920	3.8	7
84	Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. <i>Diagnostics</i> , 2019 , 9,	3.8	65
83	Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary. <i>Head and Neck</i> , 2019 , 41, 3700-3711	4.2	23
82	The currently declining incidence of cancer of unknown primary. <i>Cancer Epidemiology</i> , 2019 , 61, 139-141	2.8	34
81	Paraneoplastic syndromes in cancers of unknown primary: An unknown field for oncologists. <i>Bulletin Du Cancer</i> , 2019 , 106, 590-603	2.4	5
80	Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 251-261	3	19
79	Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder. <i>Clinical and Translational Oncology</i> , 2019 , 21, 280-288	3.6	2
78	The role of prophylactic gastrectomy in patients with juvenile polyposis syndrome. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019 , 43, e42-e43	2.4	1
77	Factors associated with the time to first palliative care consultation in Lebanese cancer patients. <i>Supportive Care in Cancer</i> , 2019 , 27, 1529-1533	3.9	4
76	A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. <i>Cancer Treatment Reviews</i> , 2019 , 72, 37-44	14.4	17
75	Causes of death in older patients with cancer: Experience of a tertiary care center in Lebanon. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 365-367	3.6	
74	Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn's Disease: A Systematic Review and Network Meta-Analysis of Prospective Trials. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 409-417	3	13
73	Total Parenteral Nutrition in Middle Eastern Cancer Patients at End of Life: Is it Justified?. <i>gulf journal of oncology, The</i> , 2019 , 1, 21-25	0.4	
72	Evaluation of chronic kidney disease in cancer patients: is there a preferred estimation formula?. <i>Internal Medicine Journal</i> , 2018 , 48, 1382-1388	1.6	3
71	Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. <i>Breast Care</i> , 2018 , 13, 121-125	2.4	

70	A prospective clinical study of the implications of IL-8 in the diagnosis, aggressiveness and prognosis of prostate cancer. <i>Future Science OA</i> , 2018 , 4, FSO266	2.7	4
69	Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. <i>European Journal of Cancer</i> , 2018 , 91, 171-173	7.5	19
68	Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?. <i>Progres En Urologie</i> , 2018 , 28, 18-24	0.9	7
67	The current evidence for a biomarker-based approach in cancer of unknown primary. <i>Cancer Treatment Reviews</i> , 2018 , 67, 21-28	14.4	25
66	A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. <i>Immunotherapy</i> , 2018 , 10, 657-663	3.8	10
65	Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?. <i>Future Oncology</i> , 2018 , 14, 891-895	3.6	3
64	Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e197-e200	2	1
63	Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience. <i>Journal of Gastrointestinal Cancer</i> , 2018 , 49, 21-24	1.6	3
62	Geriatric cancer trends in the Middle-East: Findings from Lebanese cancer projections until 2025. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 120-123	3.6	2
61	Prognostic utility of neutrophil-to-lymphocyte and platelets-to-lymphocyte ratio in predicting biochemical recurrence post robotic prostatectomy. <i>Biomarkers in Medicine</i> , 2018 , 12, 841-848	2.3	8
60	A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 130, 60-69	7	14
59	Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country: Real-life single institutional experience. <i>Journal of Cancer Research and Therapeutics</i> , 2018 , 14, 1112-1116	1.2	2
58	Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in Crohn's disease: The controversy remains. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018 , 42, e16-e18	2.4	4
57	Is there a role for the platelet-to-lymphocyte ratio in chronic lymphocytic leukemia?. <i>Future Science OA</i> , 2018 , 4, FSO344	2.7	1
56	Liquid biopsy: a new diagnostic, predictive and prognostic window in cancers of unknown primary. <i>European Journal of Cancer</i> , 2018 , 105, 28-32	7.5	16
55	The nephrotoxicity of immune checkpoint inhibitor-based combinations. <i>European Journal of Cancer</i> , 2018 , 103, 274-278	7.5	2
54	The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. <i>Immunotherapy</i> , 2018 , 10, 1047-1052	3.8	6
53	CA 15-3 predicting breast cancer relapse: beware of vitamin B12 deficiency. <i>Personalized Medicine</i> , 2018 , 15, 163-165	2.2	0

52	Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. <i>Cancer Treatment Reviews</i> , 2018 , 68, 69-79	14.4	36
51	Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinix failure? A single institutional retrospective analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017 , 41, e26-e28	2.4	7
50	An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents. <i>Bulletin Du Cancer</i> , 2017 , 104, 385-387	2.4	2
49	Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence. <i>Therapeutic Advances in Urology</i> , 2017 , 9, 73-80	3.2	8
48	Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. <i>Immunotherapy</i> , 2017 , 9, 309-311	3.8	9
47	Viral-induced Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 438-442	2	11
46	Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole. <i>Anti-Cancer Drugs</i> , 2017 , 28, 931-933	2.4	0
45	Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. <i>Immunotherapy</i> , 2017 , 9, 451-460	3.8	9
44	Abridged geriatric assessment is a better predictor of overall survival than the Karnofsky Performance Scale and Physical Performance Test in elderly patients with cancer. <i>Journal of Geriatric Oncology</i> , 2017 , 8, 128-132	3.6	19
43	Oxidative stress and prostatic diseases. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 723-728	1.6	25
42	MP166EVALUATION OF CHRONIC KIDNEY DISEASE IN CANCER PATIENTS: IS THERE STILL A ROLE FOR THE COCKROFT-GAULT ESTIMATION. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, iii489-iii490	4.3	
41	Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety. <i>Future Oncology</i> , 2017 , 13, 2709-2717	3.6	5
40	Management of stage III non-small cell lung cancer. <i>Seminars in Oncology</i> , 2017 , 44, 163-177	5.5	27
39	Withholding life-sustaining therapy in the emergency department: The perspective of emergency physicians in a conservative society. <i>Progress in Palliative Care</i> , 2017 , 25, 27-31	1	1
38	The role of palliative care in the last month of life in elderly cancer patients. <i>Supportive Care in Cancer</i> , 2017 , 25, 599-605	3.9	5
37	The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?. <i>Future Oncology</i> , 2017 , 13, 2785-2790	3.6	3
36	Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. <i>International Journal of Hematologic Oncology</i> , 2017 , 6, 105-111	1	1
35	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017 , 10, 3363-3372	4.4	8

34	Immunotherapies in sarcoma: Updates and future perspectives. <i>World Journal of Clinical Oncology</i> , 2017 , 8, 145-150	2.5	9
33	Epidemiology and Survival Analysis of Gastrointestinal Stromal Tumors in Lebanon: Real-life study from a Hospital tumor registry 2000-2015. <i>gulf journal of oncology, The</i> , 2017 , 1, 38-42	0.4	3
32	Bladder and vaginal transitional cell carcinoma: A case report. <i>Oncology Letters</i> , 2016 , 12, 2181-2183	2.6	5
31	The role of video games in facilitating the psychomotor skills training in laparoscopic surgery. <i>Gynecological Surgery</i> , 2016 , 13, 419-424	1.7	5
30	Prediction of preterm delivery by second trimester inflammatory biomarkers in the amniotic fluid. <i>Cytokine</i> , 2016 , 85, 67-70	4	9
29	Validation of the EORTC QLQ-INFO 25 questionnaire in Lebanese cancer patients: Is ignorance a Bliss?. <i>Quality of Life Research</i> , 2016 , 25, 1597-604	3.7	3
28	Acquired factor inhibitor in a patient with monoclonal gammopathy of undetermined significance responding to rituximab. <i>Blood Coagulation and Fibrinolysis</i> , 2016 , 27, 822-824	1	
27	Value of electrocardiograms ordered by junior medical officers in the emergency department. <i>Internal Medicine Journal</i> , 2016 , 46, 105-8	1.6	
26	An Unusual Case of Oral Metastasis from Rectal Adenocarcinoma Precipitated by Iatrogenicity. <i>Journal of Gastrointestinal Cancer</i> , 2016 , 47, 336-7	1.6	
25	Pancreatic small cell cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 276-280	2.4	2
24	Treatment of cancer patients in their last month of life: aimless chemotherapy. <i>Supportive Care in Cancer</i> , 2016 , 24, 1603-8	3.9	18
23	Characteristics of Incident Testicular Cancer in Lebanon - 1990-2015 Single Institutional Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 1899-902	1.7	3
22	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2016 , 22, 10124-10130	5.6	19
21	Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 745-750	3.4	14
20	Tirofiban-Induced Thrombocytopenia Occurring with Crohn's Disease. <i>Case Reports in Cardiology</i> , 2016 , 2016, 4605139	0.6	1
19	Levator Ani Necrosis: An Exceptional Complication Occurring after "High Intensity Focused Ultrasound" of the Prostate. <i>Case Reports in Urology</i> , 2016 , 2016, 3920976	0.5	
18	Morvan Syndrome Secondary to Thymic Carcinoma in a Patient with Systemic Lupus Erythematosus. <i>Case Reports in Neurological Medicine</i> , 2016 , 2016, 9142486	0.7	6
17	Immune checkpoint inhibitors renal side effects and management. <i>Immunotherapy</i> , 2016 , 8, 1417-1425	3.8	8

16	Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2016 , 34, 474-80	4.3	8
15	Data on clinical significance of second trimester inflammatory biomarkers in the amniotic fluid in predicting preterm delivery. <i>Data in Brief</i> , 2016 , 9, 47-50	1.2	1
14	Ciprofloxacin and imipenem resistance and cross-resistance in <i>Pseudomonas aeruginosa</i> : A single institution experience. <i>American Journal of Infection Control</i> , 2016 , 44, 1736-1737	3.8	4
13	Onconephrology: What Should the Internist Know About Targeted Therapy in Solid Tumors?. <i>Iranian Journal of Kidney Diseases</i> , 2016 , 10, 169-75	0.9	3
12	Unusual Destruction of the Nasal Septum. <i>gulf journal of oncology, The</i> , 2016 , 1, 61-63	0.4	
11	Characteristics of incident female breast cancer in Lebanon, 1990-2013: Descriptive study of 612 cases from a hospital tumor registry. <i>Cancer Epidemiology</i> , 2015 , 39, 303-6	2.8	13
10	Successful eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, e23-4	2.4	3
9	Pseudo-Guillain-Barré syndrome masking acute myeloid leukemia relapse: Brief report and review. <i>Leukemia Research Reports</i> , 2015 , 4, 42-4	0.6	1
8	Experience of morning reports in the emergency department. <i>Internal Medicine Journal</i> , 2015 , 45, 780-3	1.6	3
7	Factor XIII deficiency revealed by spontaneous intramedullary hemorrhage: confirmation of a severe mutation. <i>Blood Coagulation and Fibrinolysis</i> , 2015 , 26, 586-7	1	
6	Isolated Celiac and Splenic Artery Dissection: A Case Report and Review of the Literature. <i>Case Reports in Vascular Medicine</i> , 2015 , 2015, 194079	0.5	4
5	Solitary Laryngeal Metastasis from Transitional Cell Carcinoma of the Kidney: Clinical Case and Review of the Literature. <i>Case Reports in Otolaryngology</i> , 2015 , 2015, 595283	0.6	1
4	The Forgotten Complication of Recurrent Nephrolithiasis: "Squamous Cell Carcinoma of the Renal Pelvis"-A Case and Review of the Literature. <i>Case Reports in Urology</i> , 2015 , 2015, 298317	0.5	
3	Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review. <i>Journal of Bone Oncology</i> , 2015 , 4, 77-9	4.5	8
2	BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 3294-8	1.4	2
1	Optimum chemotherapy for the management of advanced biliary tract cancer. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4121-5	5.6	9